title: Bone and the perimenopause.
abstract: Loss of ovarian function has a profound impact on female skeletal health. Bone mineral density findings from the Study of Women's Health Across the Nation demonstrate an accelerated rate of bone loss during the menopausal transition. The greatest reduction occurs in the year before the final menstrual period and the first 2 years thereafter. Clinical management includes maintenance of adequate dietary calcium and vitamin D intake, attention to modifiable risk factors, and osteoporosis screening. Indications, benefits, and risks of pharmacologic osteoporosis therapy should be assessed individually; there are currently no established guidelines addressing the treatment and prevention of osteoporosis in perimenopausal women.
authors.affiliation: Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA. Joan.C.Lo@kp.org
authors.forename: Joan C
authors.initials: JC
authors.lastname: Lo
authors.forename: Sherri-Ann M
authors.initials: SA
authors.lastname: Burnett-Bowie
authors.forename: Joel S
authors.initials: JS
authors.lastname: Finkelstein
mesh_terms: D015502:Absorptiometry, Photon; D015519:Bone Density; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D006728:Hormones / Q000097:blood; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy / Q000208:ethnology / Q000503:physiopathology*; D047648:Perimenopause / Q000097:blood / Q000502:physiology*
chemical_list: D006728:Hormones